339 related articles for article (PubMed ID: 32817629)
21. Serum lipid levels associated with increased risk for cardiovascular disease is associated with highly active antiretroviral therapy (HAART) in HIV-1 infection.
Koppel K; Bratt G; Eriksson M; Sandström E
Int J STD AIDS; 2000 Jul; 11(7):451-5. PubMed ID: 10919487
[TBL] [Abstract][Full Text] [Related]
22. Increased carotid intima media thickness and cardiac biomarkers in HIV infected children.
McComsey GA; O'Riordan M; Hazen SL; El-Bejjani D; Bhatt S; Brennan ML; Storer N; Adell J; Nakamoto DA; Dogra V
AIDS; 2007 May; 21(8):921-7. PubMed ID: 17457085
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of some markers of subclinical atherosclerosis in Egyptian young adult males with abdominal obesity.
Abdou AS; Magour GM; Mahmoud MM
Br J Biomed Sci; 2009; 66(3):143-7. PubMed ID: 19839225
[TBL] [Abstract][Full Text] [Related]
24. The role of the tissue factor and its inhibitor in the development of subclinical atherosclerosis in people living with HIV.
Barska K; Kwiatkowska W; Knysz B; Arczyńska K; Karczewski M; Witkiewicz W
PLoS One; 2017; 12(7):e0181533. PubMed ID: 28749986
[TBL] [Abstract][Full Text] [Related]
25. HIV disease, metabolic dysfunction and atherosclerosis: A three year prospective study.
Low H; Hoang A; Pushkarsky T; Dubrovsky L; Dewar E; Di Yacovo MS; Mukhamedova N; Cheng L; Downs C; Simon G; Saumoy M; Hill AF; Fitzgerald ML; Nestel P; Dart A; Hoy J; Bukrinsky M; Sviridov D
PLoS One; 2019; 14(4):e0215620. PubMed ID: 30998801
[TBL] [Abstract][Full Text] [Related]
26. Low-density lipoprotein size and lipoprotein-associated phospholipase A2 in HIV-infected patients switching to abacavir or tenofovir.
Saumoy M; Ordoñez-Llanos J; Martínez E; Barragán P; Ribera E; Bonet R; Knobel H; Negredo E; Loncá M; Curran A; Gatell JM; Podzamczer D;
Antivir Ther; 2011; 16(4):459-68. PubMed ID: 21685533
[TBL] [Abstract][Full Text] [Related]
27. Marker of Endothelial Dysfunction Asymmetric Dimethylarginine Is Elevated in HIV Infection but Not Associated With Subclinical Atherosclerosis.
Haissman JM; Haugaard AK; Knudsen A; Kristoffersen US; Seljeflot I; Pedersen KK; Lebech AM; Hasbak P; Kjær A; Ostrowski SR; Gerstoft J; Trøseid M; Nielsen SD
J Acquir Immune Defic Syndr; 2016 Dec; 73(5):507-513. PubMed ID: 27509250
[TBL] [Abstract][Full Text] [Related]
28. Nonconcordance between subclinical atherosclerosis and the calculated Framingham risk score in HIV-infected patients: relationships with serum markers of oxidation and inflammation.
Parra S; Coll B; Aragonés G; Marsillach J; Beltrán R; Rull A; Joven J; Alonso-Villaverde C; Camps J
HIV Med; 2010 Apr; 11(4):225-31. PubMed ID: 19845792
[TBL] [Abstract][Full Text] [Related]
29. Atherogenic properties of LDL particles after switching from Truvada or Kivexa plus lopinavir/r to lamivudine plus lopinavir/r: OLE-MET substudy.
Saumoy M; Tiraboschi JM; Ordoñez-Llanos J; Ribera E; Domingo P; Mallolas J; Curto J; Gatell JM; Podzamczer D
HIV Clin Trials; 2017 Mar; 18(2):49-53. PubMed ID: 28081673
[TBL] [Abstract][Full Text] [Related]
30. Changes of metabolic and inflammatory markers in HIV infection: glucose, lipids, serum Hs-CRP and myeloperoxidase.
Borato DC; Parabocz GC; Ribas SR; Kalva-Filho CA; Borba LM; Ito CA; Bail L; dos Santos FA; Vellosa JC
Metabolism; 2012 Oct; 61(10):1353-60. PubMed ID: 22480983
[TBL] [Abstract][Full Text] [Related]
31. Subclinical atherosclerosis among HIV-infected adults attending HIV/AIDS care at two large ambulatory HIV clinics in Uganda.
Ssinabulya I; Kayima J; Longenecker C; Luwedde M; Semitala F; Kambugu A; Ameda F; Bugeza S; McComsey G; Freers J; Nakanjako D
PLoS One; 2014; 9(2):e89537. PubMed ID: 24586854
[TBL] [Abstract][Full Text] [Related]
32. Low-density lipoprotein size and subclasses are markers of clinically apparent and non-apparent atherosclerosis in type 2 diabetes.
Berneis K; Jeanneret C; Muser J; Felix B; Miserez AR
Metabolism; 2005 Feb; 54(2):227-34. PubMed ID: 15690318
[TBL] [Abstract][Full Text] [Related]
33. Cardiovascular biomarkers in vertically HIV-infected children without metabolic abnormalities.
Sainz T; Diaz L; Navarro ML; Rojo P; Blázquez D; Ramos JT; de José MI; Álvarez-Fuente M; Serrano-Villar S; Mellado MJ; Muñoz-Fernández MA;
Atherosclerosis; 2014 Apr; 233(2):410-414. PubMed ID: 24530771
[TBL] [Abstract][Full Text] [Related]
34. Changes in lipids and lipoprotein particle concentrations after interruption of antiretroviral therapy.
Lampe FC; Duprez DA; Kuller LH; Tracy R; Otvos J; Stroes E; Cooper DA; Hoy J; Paton NI; Friis-Møller N; Neuhaus J; Liappis AP; Phillips AN;
J Acquir Immune Defic Syndr; 2010 Jul; 54(3):275-84. PubMed ID: 20658749
[TBL] [Abstract][Full Text] [Related]
35. Immunological profiling of tuberculosis-associated immune reconstitution inflammatory syndrome and non-immune reconstitution inflammatory syndrome death in HIV-infected adults with pulmonary tuberculosis starting antiretroviral therapy: a prospective observational cohort study.
Ravimohan S; Tamuhla N; Steenhoff AP; Letlhogile R; Nfanyana K; Bellamy SL; MacGregor RR; Gross R; Weissman D; Bisson GP
Lancet Infect Dis; 2015 Apr; 15(4):429-38. PubMed ID: 25672566
[TBL] [Abstract][Full Text] [Related]
36. [Danlou Tablet Fought against Inflammatory Reaction in Atherosclerosis Rats with Intermingled Phlegm and Blood Stasis Syndrome and Its Mechanism Study].
Chen J; Cai HW; Miao J; Xu XM; Mao W
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2016 Jun; 36(6):703-8. PubMed ID: 27491230
[TBL] [Abstract][Full Text] [Related]
37. Potential cardiovascular disease risk markers among HIV-infected women initiating antiretroviral treatment.
Kaplan RC; Landay AL; Hodis HN; Gange SJ; Norris PJ; Young M; Anastos K; Tien PC; Xue X; Lazar J; Parrinello CM; Benning L; Tracy RP
J Acquir Immune Defic Syndr; 2012 Aug; 60(4):359-68. PubMed ID: 22592585
[TBL] [Abstract][Full Text] [Related]
38. Association of Macrophage Inflammation Biomarkers With Progression of Subclinical Carotid Artery Atherosclerosis in HIV-Infected Women and Men.
Hanna DB; Lin J; Post WS; Hodis HN; Xue X; Anastos K; Cohen MH; Gange SJ; Haberlen SA; Heath SL; Lazar JM; Liu C; Mack WJ; Ofotokun I; Palella FJ; Tien PC; Witt MD; Landay AL; Kingsley LA; Tracy RP; Kaplan RC
J Infect Dis; 2017 May; 215(9):1352-1361. PubMed ID: 28199691
[TBL] [Abstract][Full Text] [Related]
39. Hepatitis C infection is associated with lower lipids and high-sensitivity C-reactive protein in HIV-infected men.
Floris-Moore M; Howard AA; Lo Y; Schoenbaum EE; Arnsten JH; Klein RS
AIDS Patient Care STDS; 2007 Jul; 21(7):479-91. PubMed ID: 17651029
[TBL] [Abstract][Full Text] [Related]
40. Infection duration and inflammatory imbalance are associated with atherosclerotic risk in HIV-infected never-smokers independent of antiretroviral therapy.
Desvarieux M; Boccara F; Meynard JL; Bastard JP; Mallat Z; Charbit B; Demmer RT; Haddour N; Fellahi S; Tedgui A; Cohen A; Capeau J; Boyd A; Girard PM
AIDS; 2013 Oct; 27(16):2603-14. PubMed ID: 24100713
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
